Lynparza
(Fluzoparib)Phase 3Small molecule
Fluzoparib is used to treat certain cancers, particularly those with specific genetic mutations like BRCA mutations, by blocking a protein that helps cancer cells repair their DNA.[1] Lynparza is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Lynparza is one of 284 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 3.
8
Indications
55
Total Trials
22
Active Trials
283
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer14 trials
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Not yet recruiting·—·Phase 3·NCT06539091·51 enrolled
Show 11 more trials
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 3·NCT06188455·37 enrolled
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
Unknown status·TThe Second Affiliated Hospital of Shandong First Medical University·Phase 2·NCT05170594·60 enrolled
Breast Cancer12 trials
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled
Show 9 more trials
Small Cell Lung Cancer3 trials
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Not yet recruiting·—·Phase 1/2·NCT07141771·100 enrolled
Pancreatic Cancer3 trials
19 more indications
Function2 trials
Recurrent Ovarian Cancer1 trial
Endometrial Cancer1 trial
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Recruiting·—·Phase 2·NCT06413992·117 enrolled
Non-Small Cell Lung Cancer1 trial
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04828395·65 enrolled
Renal Cell Carcinoma1 trial
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04535687·1 enrolled
Advanced Solid Malignancies1 trial
Metastatic Colorectal Cancer1 trial
Patients With Solid Tumors1 trial
Ovarian Carcinoma1 trial
Soft Tissue Sarcoma1 trial
Neoadjuvant Therapy1 trial
Preoperative1 trial
Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)
Completed·—·Phase 2·NCT05938374·52 enrolled
Gastric Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluzoparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details